A Study of Replagal in Treatment-naïve Adults With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Sponsor: Shire
Terminated
Study closed due to enrolment challenges, not for any safety issues
Other terminated trials from Shire
Other Fabry Disease trials with similar outcome
Listed as NCT04840667, this PHASE3 trial focuses on Fabry Disease and remains terminated or withdrawn. Sponsored by Shire, it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2022 — Jun 2023 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Almería, Spain , Athens, Greece , Barcelona, Spain , Berlin, Germany , Calgary, Canada , Coimbra, Portugal , Guimarães, Portugal , Halifax, Canada , Heraklion, Greece and 17 more locations